Market Tracker

02/24 5:16pm ET

Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

131.54
Delayed Data
As of Feb 24
 +1.10 / +0.84%
Today’s Change
109.12
Today|||52-Week Range
162.00
+7.51%
Year-to-Date
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
Feb 22 / Zacks.com - Paid Partner Content
Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y
Feb 16 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
Feb 22 / Zacks.com - Paid Partner Content
Alexion (ALXN) Misses on Q4 Earnings and Revenues
Feb 16 / Zacks.com - Paid Partner Content
Forget Alexion, Buy these 4 Biotech Stocks Instead
Feb 20 / Zacks.com - Paid Partner Content
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
Feb 15 / Zacks.com - Paid Partner Content
Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS
Feb 20 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close130.44
Today’s open131.37
Day’s range130.00 - 132.46
Volume1,657,255
Average volume (3 months)2,861,478
Market cap$29.3B
Dividend yield--
Data as of 3:59pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)+162.69%
Earnings growth (this year)+14.44%
Earnings growth (next 5 years)+21.40%
Revenue growth (last year)+24.05%
P/E ratio74.7
Price/Sales9.01
Price/Book--

Competitors

 Today’s
change
Today’s
% change
BAXBaxter International...+0.10+0.20%
ZTSZoetis Inc+0.30+0.56%
INCYIncyte Corp+9.26+7.59%
MYLMylan NV-0.17-0.40%
Data as of 4:02pm ET, 02/24/2017

Financials

Next reporting dateApril 27, 2017
EPS forecast (this quarter)$1.25
Annual revenue (last year)$3.1B
Annual profit (last year)$399.0M
Net profit margin12.94%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
David Richard Brennan
Executive Vice President-
Global Operations
Julie O'Neill
Corporate headquarters
New Haven, Connecticut

Forecasts